File(s) stored somewhere else
Please note: Linked content is NOT stored on University of Illinois at Chicago and we can't guarantee its availability, quality, security or accept any liability.
KIF13B - mediated VEGFR2 trafficking is essential for vascular leakage and metastasis in vivo
VEGF-A induces vascular leakage and angiogenesis via activating the cell surface localized receptor VEGF receptor 2 (VEGFR2). The amount of available VEGFR2 at the cell surface is however tightly regulated by trafficking of VEGFR2 by kinesin family 13 B (KIF13B), a plus-end kinesin motor, to the plasma membrane of endothelial cells (ECs). Competitive inhibition of interaction between VEGFR2 and KIF13B by a peptide kinesin-derived angiogenesis inhibitor (KAI) prevented pathological angiogenesis in models of cancer and eye disease associated with defective angiogenesis. Here, we show the protective effects of KAI in VEGF-A-induced vascular leakage and cancer metastasis. Using an EC-specific KIF13B knockout (Kif13biECKO) mouse model, we demonstrated the function of EC expressed KIF13B in mediating VEGF-A-induced vascular leakage, angiogenesis, tumor growth, and cancer metastasis. Thus, KIF13B-mediated trafficking of VEGFR2 to the endothelial surface has an essential role in pathological angiogenesis induced by VEGF-A, and is therefore a potential therapeutic target.
National Institutes of Health (NIH) | 1R01EY029339-01A1 | KH Yamada
National Institutes of Health (NIH) | 1R56HL128342-01A1 | KH Yamada
RPB Stein Innovation Award | AB Malik
UIC Chancellor’s Innovation Fund | KH Yamada
CitationWaters, S. B., Dominguez, J. R., Cho, H. -D., Sarich, N. A., Malik, A. B.Yamada, K. H. (2021). KIF13B - mediated VEGFR2 trafficking is essential for vascular leakage and metastasis in vivo. Life Science Alliance, 5(1). https://doi.org/10.26508/Isa.202101170
PublisherLife Science Alliance